| Date | Title | Description |
| 10.02.2026 | Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens[1] for Astigmatic Adults living with Presbyopia | The brand also expands daily disposable options for astigmatic adults with the launch of ACUVUE® OASYS MAX 1-Day for ASTIGMATISM, bringing pioneering innovation that delivers visual clarity and comfort [+],[**],[2],[3] as vision needs evolv... |
| 23.01.2024 | Ahead of Medicare drug price reform, pharma’s drug pricing has a Streisand effect | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with a look at some polarizing cancer data, a strange CEO transition, and the importanc... |
| 12.01.2024 | 7 JPM Announcements You Don’t Want to Miss | This year’s J.P. Morgan Healthcare Conference in San Francisco, which wrapped on Thursday, enabled healthcare leaders from all over the country to convene, have discussions and network. The event also featured a slew of news announcements f... |
| 05.12.2023 | Carmot’s chance of beating the odds in the biotech market just ended | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with a special thanks to everyone who joined us for STAT’s live event in New Yor... |
| 17.10.2023 | As Pfizer slashes revenue projections, Moderna says it “remains comfortable” | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with the latest twist in the GLP-1 saga, some drama in the world of Covid-19 booster sh... |
| 09.08.2023 | 2 recession-proof stocks for 2023 | The economy often moves in cycles of expansion and contraction. Contracting markets are also known as recession. During these times regular portfolios may not work well and risky plays like tech stocks and crypto are likely to suffer the mo... |
| 18.10.2022 | J&J holds off on volatile M&A market but has plenty of cash for a deal | While J&J racked up $23 billion in total sales for the third quarter and spun off its consumer health business, analysts want to know what the company is planning next.
Joseph Wolk
CFO Joseph Wolk said during the company’s ... |
| 20.04.2021 | JOHNSON & JOHNSON
Johnson & Johnson : Reports 2021 First-Quarter Results | New Brunswick, N.J. (April 20, 2021) - Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2021. 'Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our Pharmaceutica... |
| 14.08.2020 | Backed by Johnson & Johnson, Thirty Madison Raises $47M for Direct-to-Consumer Telehealth Brands | What You Should Know:
– Direct-to-consumer telehealth company Thirty Madison raises $47M in Series B round from Johnson & Johnson and Polaris Partners.
– Thirty Madison’s three portfolio brands — Keeps, Cove, and Evens — enables patient... |
| 12.03.2020 | Thermo Fisher, J&J partner on next-generation sequencing diagnostic for cancer clinical trials | “The ability of the Oncomine Dx Target Test to rapidly detect variants of interest from very small quantities of DNA or RNA samples makes this technology ideally suited to support development programs requiring an NGS-based workflow that de... |
| 16.12.2019 | Mauna Kea Technologies Announces Equity Investment of €7.5 Million by Johnson & Johnson Innovation | PARIS & BOSTON--(BUSINESS WIRE)--Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced a s... |
| 25.07.2018 | Philadelphia’s digital health ecosystem takes shape | In an interview with Tom Olenzak, Managing Director for Independence Blue Cross’s Strategic Innovation Portfolio, he likened this cycle of talent and capital from successful exits seeding new generations of startups to what the region saw i... |
| 18.03.2018 | Johnson & Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan for $2.1B | Johnson & Johnson (NYSE: JNJ) today announced that it has received a binding offer from Platinum Equity, a leading private investment firm, to acquire its LifeScan business for approximately $2.1 billion, subject to customary adjustment... |
| 07.08.2017 | Houston Biotech Oncolix Announces Reverse Merger, Goes Public | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
[Updated 8/7/17, 10:25 am. See below.] Houston—Oncolix, which is developing a treatment for ovarian cancer, announced Monday it has completed a reverse merger with Advanced En... |
| 17.11.2016 | J&J takes one of its top blockbuster prospects to the FDA, in search of a big approval | MorphoSys CSO Marlies Sproll
Hot on the heels of a new round of Phase III data showing that their IL-23 drug guselkumab handily beat out Humira in treating severe plaque psoriasis, J&J has submitted the drug for approv... |
| 31.10.2016 | How J&J’s Walmart relationship is inspiring its device business | The Affordable Care Act has laid the groundwork for a seismic shift in the way the medical device industry operates.
Traditionally, large companies like Johnson & Johnson built up an army of sales reps who would have relationships with ... |
| 28.10.2016 | Should J&J buy Edwards Lifesciences? | In the Medical Devices, as you know we have a very strong presence in orthopaedics and in general surgery. We keep looking for additional bolt-on acquisitions there and we have a very strong electrophysiology business in cardiovascular but ... |
| 29.05.2015 | Johnson and Johnson accepts $2B offer for vascular medical device producer, Teva reaches settlement (Morning Read) | Otsuka Pharmaceutical Co Ltd lost a lawsuit challenging the U.S. Food and Drug Administration’s decision allowing other companies to make generic versions of the it’s antipsychotic drug, Abilify. Because the FDA typically grants years of ex... |
| 28.05.2015 | J&J accepts binding offer from Cardinal Health for Cordis unit | Johnson & Johnson (NYSE:JNJ) said today that it accepted a binding offer worth about $2 billion for its Cordis stent-making arm from Cardinal Health (NYSE:CAH).
The New Brunswick, N.J.-based healthcare giant said it expects the deal to ... |
| 14.04.2015 | Pharma the lone Q1 bright spot for J&J | Johnson & Johnson (NYSE:JNJ) today said the effect of a stronger dollar pared 13.2% from its top line during the 1st quarter, but still managed to top Wall Street’s earnings forecast.
The New Brunswick, N.J.-based healthcare conglomerat... |
| 01.04.2015 | Johnson & Johnson Innovation – JJDC Makes $15 Million Investment in Vivo Capital Fund | - |
| 02.03.2015 | J&J deals Cordis to Cardinal Health for nearly $2B | Healthcare giant Johnson & Johnson (NYSE:JNJ) confirmed today that it plans to deal its Cordis stent-making arm to Cardinal Health (NYSE:CAH) for $1.94 billion.
The deal, which is worth some $1.59 billion net of tax benefits, is expecte... |
| 23.09.2014 | Surgical startup raises $25M for ablation device that reduces menstrual bleeding | Minerva has steadily raised a significant amount of capital since its 2008 launch – including this latest round, it’s received about $80 million in equity funding, according to a slew of regulatory filings. Calls to the company to detail wh... |
| 22.07.2014 | Johnson & Johnson launches $5B buyback | Johnson & Johnson (NYSE:JNJ) last night announced that its board of directors approved a $5 billion open-ended repurchase program for shares of the company’s common stock.
The buyback has no time limit and may be suspended and or discon... |
| 01.04.2014 | Carlyle officially wins Johnson & Johnson’s diagnostics biz for $4B | Johnson & Johnson (NYSE:JNJ) said late yesterday that it accepted a $4 billion offer from private equity giant Carlyle Group to acquire its Ortho-Clinical Diagnostics blood testing business.
Carlyle beat out several other PE shops with ... |
| 26.03.2014 | The 2014 Midas List: Fewer New Names And More Explosive Exits | For the third straight year, the number of newcomers to the Midas List has dropped. From 38 new names in 2012 to 25 new names in 2013, the number of entrants to this year’s List dipped even further, to 19. The data from previous years’ Mida... |
| 16.07.2013 | Johnson & Johnson’s Q2 earnings soar 172% | Shares of Johnson & Johnson (NYSE:JNJ) could spike today after the healthcare giant reported surging 2nd-quarter profits, beating Wall Street’s forecast by 9¢, and raised its earnings outlook for the rest of the year.
New Brunswick, N.J... |
| 16.07.2013 | Johnson & Johnson’s medical device business misses Q2 expectations | Johnson & Johnson‘s (NYSE:JNJ) medical device & diagnostics segment missed Wall Street’s 2nd-quarter sales forecast by some $126 million, largely due to falling sales for its diabetes business, but the healthcare giant’s orthopedic ... |
| 28.06.2013 | Shipping up to Boston: Johnson & Johnson debuts new Innovation Center | Johnson & Johnson (NYSE:JNJ) threw open the doors and cracked champagne at last night’s grand opening of its new Innovation Center, a modest 9,000-sqaure-foot space in Cambridge, Mass., it calls a "hotbed for life science innovatio... |
| 16.10.2012 | FLASH: Johnson & Johnson reports Q3 earnings slip 18%, boosts outlook | Johnson & Johnson (NYSE:JNJ) beat Wall Street’s earnings expectations and boosted its profit outlook for the rest of the year this morning before the market’s open.
The New Brunswick, N.J.-based healthcare giant posted profits of $2.63 ... |
| 18.04.2012 | DePuy ASR recall takes $271M from J&J’s Q1 bottom line | Shares of Johnson & Johnson (NYSE:JNJ) closed up a hair yesterday after the company said it added 12.5% to its bottom line, ending the day at $64.22 per share after the J&J raised its earnings guidance for the year by a pair of penn... |
| 03.04.2012 | Biomet offers $280M to acquire DePuy Orthopaedics’ trauma business | Biomet, meanwhile, just dodged a bullet of its own by agreeing to a $22 million settlement regarding U.S. allegations that it bribed doctors in countries like Brazil and China over a period of several years. The Warsaw, Indiana company desi... |
| 10.02.2012 | DePuy Orthopaedics rolls out new hip, shoulder, knee surgery technologies | Knee surgery
The newly released AOX Antioxidant Polyethylene is a new formulation of polyethylene, which is a material commonly used as a bearing surface in joint replacements. When exposed to oxygen, it creates free radicals that can weake... |
| 24.01.2012 | Johnson & Johnson takes $3 billion charge in 4Q over litigation, recalls | The company had only $218 million in profits on sales of $16.2 billion.
Last year, the company exited the stent business amidst tougher battles for market share and costly patent litigation.
Les Funtleyder, a portfolio manager with Miller T... |
| 19.07.2011 | J&J’s Q2 earnings slide 20 percent, but it still beats The Street | Johnson & Johnson (NYSE:JNJ) managed to top Wall Street’s expectations with its second-quarter results, despite posting a nearly 20 percent bottom-line slide.
The New Brunswick, N.J.-based health care products conglomerate reported prof... |
| 25.01.2011 | Medical device unit can’t overcome JNJ recall woes | How do you spell relief?
For Johnson & Johnson (NYSE:JNJ), which has been battered for months by a series of recalls involving its over-the-counter pharma products (including Rolaids), it’s not D-E-S.
Cordis Corp., the stent-making oper... |
| 19.10.2010 | J&J’s Cordis sees 35% drop in stent sales in third quarter | Taken together, however, Johnson & Johnson’s medical device and diagnostics segment managed to eke out a small top-line increase, rising 1.3 percent to $5.92 billion, compared with $5.84 billion during Q3 2009.
Taken individually, howev... |
| 28.09.2010 | Johnson & Johnson closes $480 million deal for Micrus Endovascular | Johnson & Johnson (NYSE:JNJ) closed its $480 million cash deal to acquire Micrus Endovascular Corp. (NSDQ:MEND), a San Jose, Calif.-based maker of cerebral vascular devices.
San Jose, Calif.-based Micrus specializes in “bioactive” coils... |
| 12.07.2010 | Startup Devicor Medical buys Johnson & Johnson breast care unit | The former Ethicon Endo-Surgery breast care portfolio is sold in 50 countries and includes the Mammotome Breast Biopsy System and tissue markers (MammoMARK, MicroMARK and CorMARK) used for diagnostic sampling and management of potentially d... |
| 04.06.2010 | Johnson & Johnson: Cordis Corp. is our only medical device dog | Johnson & Johnson (NYSE:JNJ) provided investors and analysts with a glimpse into its medical device operation, which it called the world’s largest.
Over the past two years, according to the presentation, the division posted $1.8 billion... |
| 18.05.2010 | FDA warns St. Jude Medical on improper cardiac catheter promotion | By Brandon Glenn
The Food & Drug Administration sent a warning letter to St. Jude Medical Inc. (NYSE:STJ) that cites the device maker for improperly promoting a cardiac ablation catheter system.
St. Jude promoted its Epicor cardiac abla... |
| 26.01.2010 | Johnson & Johnson’s Q4 net slumps 19 percent on restructuring charge | The $1 billion Johnson & Johnson (NYSE:JNJ) spent on restructuring during the fourth quarter exacted a steep toll on its bottom line, dragging profits down 18.7 percent to $2.21 billion during the three months ended Dec. 31, 2009.
But t... |
| 10.12.2009 | Second state AG subpoenas Medtronic | Medtronic Inc. (NYSE:MDT) said California attorney general Jerry Brown is demanding documents from its cardiac rhythm management business, making Brown the second AG this year to subpoena the Minneapolis medical device monolith.
Medtronic s... |
| 04.11.2009 | Johnson & Johnson plans to cut up to 7 percent of global workforce – MedCity Morning Read, Nov. 4, 2009 | Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent, and patient experience has nev... |
| - | Johnson & Johnson narrowly tops quarterly estimates as pharmaceutical, medtech sales jump | Johnson & Johnson reported fourth-quarter earnings and revenue that narrowly edged out Wall Street’s expectations.
Sales in the company’s pharmaceutical and medical devices businesses surged.
For full year 2024, J&J is forecasting s... |
| - | Johnson & Johnson plans to cut up to 7 percent of global workforce – MedCity Morning Read, Nov. 4, 2009 | Image by Getty Images via Daylife
NEW BRUNSWICK, New Jersey – Health-products behemoth Johnson & Johnson announced Tuesday that it will cut 6 to 7 percent of its workforce, which amounts to as many as 8,200 jobs, The Wall Street Journ... |
| - | Biomet offers $280M to acquire DePuy Orthopaedics’ trauma business | Biomet Inc. has made a $280 million binding offer to acquire the worldwide trauma business of Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Orthopaedics Inc.
“This transaction will provide Biomet with a much stronger presence in the glo... |
| - | J&J’s Cordis sees 35% drop in stent sales in third quarter | Cordis Corp., the stent-making operation of Johnson & Johnson (NYSE:JNJ), saw overall sales slip nearly 7 percent and stent sales drop 35.5 percent during the third quarter.
The New Brunswick, New Jersey-based medical products conglomer... |
| - | Startup Devicor Medical buys Johnson & Johnson breast care unit | Devicor Medical Products Inc., the Pleasant Valley, Wisconsin, fledgling holding company backed by Chicago private equity firm GTCR Golder Rauner LLC, has made its first acquisition: the breast care business of Johnson & Johnson’s Ethic... |
| - | Surgical startup raises $25M for ablation device that reduces menstrual bleeding | Bay Area startup Minerva Surgical has just raised $25 million for its device that treats menorrhagia, or abnormally heavy menstrual bleeding in women, according to a regulatory filing.
Minerva is developing a device, called the Aurora Endom... |
| - | Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs | Big pharmaceutical companies like Bristol Myers Squibb, Merck and Johnson & Johnson face so-called patent cliffs that will put tens of billions of dollars in sales at risk between now and 2030.
That refers to when patents expire for one... |
| - | Thermo Fisher, J&J partner on next-generation sequencing diagnostic for cancer clinical trials | A unit of Johnson & Johnson is working with one of the country’s largest makers of diagnostics and lab-testing equipment to develop a companion diagnostic for cancer clinical trials.
Waltham, Massachusetts-based Thermo Fisher Scientific... |
| - | How J&J’s Walmart relationship is inspiring its device business | The Affordable Care Act has laid the groundwork for a seismic shift in the way the medical device industry operates.
Traditionally, large companies like Johnson & Johnson built up an army of sales reps who would have relationships with ... |
| - | Philadelphia’s digital health ecosystem takes shape | This article is sponsored by the CEO Council for Growth, an initiative of the Chamber of Commerce for Greater Philadelphia .
Philadelphia is at a significant junction in its development as a digital health hub. If you use the CEO Council fo... |
| - | DePuy Orthopaedics rolls out new hip, shoulder, knee surgery technologies | DePuy Orthopaedics launched several new surgical products this week for knee, shoulder and hip revisions.
The Johnson & Johnson (NYSE:JNJ) subsidiary accounted for $5.8 billion in sales in 2011, but those sales were offset by $521 milli... |
| - | Should J&J buy Edwards Lifesciences? | Last week, in an earnings call with analysts, Dominic Caruso, chairman and CEO of Johnson & Johnson, indicated that the diversified conglomerate is interested in the structural heart space.
Here’s what Caruso said in response to an anal... |
